Insider Selling: Tactile Systems Technology, Inc. (NASDAQ:TCMD) Director Sells $159,147.90 in Stock

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Director Daniel L. Reuvers sold 10,938 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $14.55, for a total value of $159,147.90. Following the transaction, the director now owns 242,942 shares in the company, valued at $3,534,806.10. The trade was a 4.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Tactile Systems Technology Stock Performance

TCMD opened at $14.52 on Thursday. The stock has a market cap of $342.45 million, a P/E ratio of 20.74 and a beta of 1.20. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.36 and a quick ratio of 3.80. The stock’s 50 day simple moving average is $17.09 and its 200 day simple moving average is $15.72. Tactile Systems Technology, Inc. has a 1-year low of $11.12 and a 1-year high of $21.10.

Tactile Systems Technology (NASDAQ:TCMD) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.09. The business had revenue of $85.59 million for the quarter, compared to analysts’ expectations of $85.39 million. Tactile Systems Technology had a return on equity of 9.37% and a net margin of 5.79%. As a group, equities analysts anticipate that Tactile Systems Technology, Inc. will post 0.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. B. Riley cut Tactile Systems Technology from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $23.00 to $18.00 in a research report on Wednesday, February 19th. StockNews.com cut Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 16th. BTIG Research cut Tactile Systems Technology from a “buy” rating to a “neutral” rating in a report on Tuesday, November 5th. Finally, Oppenheimer cut Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.

Institutional Investors Weigh In On Tactile Systems Technology

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Tactile Systems Technology by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 1,483,692 shares of the company’s stock valued at $25,416,000 after buying an additional 4,509 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Tactile Systems Technology by 8.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 901,551 shares of the company’s stock valued at $15,444,000 after buying an additional 67,934 shares during the last quarter. Wasatch Advisors LP grew its holdings in Tactile Systems Technology by 9.8% during the 3rd quarter. Wasatch Advisors LP now owns 727,194 shares of the company’s stock valued at $10,624,000 after buying an additional 64,684 shares during the last quarter. Royce & Associates LP grew its holdings in Tactile Systems Technology by 2.5% during the 3rd quarter. Royce & Associates LP now owns 612,979 shares of the company’s stock valued at $8,956,000 after buying an additional 14,780 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Tactile Systems Technology by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 558,667 shares of the company’s stock valued at $8,164,000 after buying an additional 8,422 shares during the last quarter. Institutional investors and hedge funds own 83.43% of the company’s stock.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.